With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The firm plans to seek full commercial approval for its assay, which integrates biomarker identification with a patient's electronic medical record, later this year.
BGI will study pancreatic cancer with a group at Johns Hopkins and develop a diagnostic test for preterm birth detection with Mount Sinai Hospital researchers.
Coming one year after LabCorp's acquisition of Mount Sinai's Clinical Outreach business, the new partnership will standardize lab operations at seven hospitals.
The two parties are exploring opportunities to collaborate on research projects, including next-generation genomics and molecular diagnostic test development.
